Welcome to Decoding Bio’s BioByte: each week our writing collective highlight notable news—from the latest scientific papers to the latest funding rounds—and everything in between.
Given your interest in Biotech manufacturing, you might enjoy my recent biotech piece on eXoZymes Inc. They’ve just commercially launched a cell-free enzyme-based biomanufacturing platform that converts biofeedstocks into targeted chemical products.
Plus they just announced their first subsidary which synthesises N-trans-caffeoyltyramine (NCT) to treat MASLD/MASH. Very very interesting compound that has immense potential
hey Decoding!
Given your interest in Biotech manufacturing, you might enjoy my recent biotech piece on eXoZymes Inc. They’ve just commercially launched a cell-free enzyme-based biomanufacturing platform that converts biofeedstocks into targeted chemical products.
Plus they just announced their first subsidary which synthesises N-trans-caffeoyltyramine (NCT) to treat MASLD/MASH. Very very interesting compound that has immense potential
https://www.slack-capital.com/p/exozymes-research-report